Pharma reps aren't talking about drug risks, study finds
Doctors aren’t getting the skinny on drug side effects from pharma reps, a new study finds. Even the most serious risks are often overlooked, the survey found. And while probes of
«Laws in all three countries require sales representatives to provide information on harm as well as benefits," lead author Barbara Mintzes of the University of British Columbia said in a release. «But no one is monitoring these visits and there are next to no sanctions for misleading or inaccurate promotion.»
Researchers surveyed 255 family physicians in Canada, France and the
In fact, serious risks were mentioned only 6% of the
French reps were the most conscientious. They offered info on serious risks during 40% of their visits. Canadian reps were least likely to share risk information; Vancouver salespeople disclosed no potential harms for 66% of the drugs they promoted, the study found. Significant contraindications came up only 14% of the time in both Vancouver and Montreal. The U.S. reps were slightly better, sharing those contraindications 17% of the time.